**CLAIMS**

1. Use of a type I interferon (IFN) receptor (IFNR) inhibitor in the manufacture of a medicament for treating systemic lupus erythematosus (SLE) in a subject in need thereof, wherein a therapeutically effective amount of the medicament is to be administered to the subject, wherein at baseline the subject has a low type I IFN gene signature (IFNGS), wherein the IFNR inhibitor reduces SLE disease activity in the subject, and wherein the IFNR inhibitor is an antibody comprising:

    a. a heavy chain variable region complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO: 3;

    b. a heavy chain variable region complementarity determining region 2 (HCDR2) comprising the amino acid sequence of SEQ ID NO: 4;

    c. a heavy chain variable region complementarity determining region 3 (HCDR3) comprising the amino acid sequence of SEQ ID NO: 5;

    d. a light chain variable region complementarity determining region 1 (LCDR1) comprising the amino acid sequence SEQ ID NO: 6;

    e. a light chain variable region complementarity determining region 2 (LCDR2) comprising the amino acid sequence SEQ ID NO: 7; and

    f. a light chain variable region complementarity determining region 3 (LCDR3) comprising the amino acid sequence SEQ ID NO: 8,

    wherein the IFNGS of the subject at baseline is measurable by a 4-gene quantitative polymerase chain reaction-based test, wherein the test measures IFI27, IFI44, IFI44L and RSAD2 expression in the whole blood of the subject.

2. The use of any preceding claim, wherein the reducing SLE disease activity in the subject comprises a BILAG-Based Composite Lupus Assessment (BICLA) response in the subject.

3. The use of any preceding claim, wherein the subject has moderate to severe SLE.

4. The use of any preceding claim, wherein the antibody comprises:

    a. a human heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1; and

    b. a human light chain variable region comprising the amino acid sequence of SEQ ID NO: 2.

5. The use of any preceding claim, wherein the antibody is anifrolumab.

6. The use of claim 5, wherein the IFNR inhibitor is to be administered to the subject in a dose of 300 mg.

7. The use of claim 5 or 6, wherein a dose of the IFNR inhibitor is to be administered to the subject every 4 weeks.

8. The use of any preceding claim, wherein the IFNR inhibitor is to be administered to the subject intravenously.

9. The use of any of claims 1 to 8, wherein the IFNR inhibitor is to be administered to the subject subcutaneously.

10. The use of any preceding claim, wherein the subject is positive for anti-dsDNA, anti-nuclear or anti-Smith antibodies at baseline.